SiSaf

SiSaf is a biopharmaceutical company developing RNA therapeutics using its proprietary platform, which combines bioabsorbable silicon with organic lipid materials to improve the stability, safety, and transfection efficiency of nucleic acid payloads.

The platform addresses known limitations of conventional lipid nanoparticle delivery systems.

SiSaf's internal pipeline targets rare genetic disorders and oncology, and the company licenses its delivery technology to pharmaceutical partners across a range of indications.